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Abstract 
 
Purpose 
The reduction in acquired infections (AI) due to methicillin-resistant Staphylococcus aureus (MRSA) with the 
mupirocin/chlorhexidine (M/C) decontamination regimen has not been well studied in intubated patients. We performed post 
hoc analysis of a prior trial to assess the impact of M/C on MRSA AI and colonization.  
AQ1 
AQ2 
Methods 
We conducted a multicenter, placebo-controlled, randomized, double-blind study with the primary aim to reduce all-cause 
AI. The two regimens used [topical polymyxin and tobramycin (P/T), nasal mupirocin with chlorhexidine body wash (M/C), 
or corresponding placebos for each regimen] were administered according to a 2  × 2 factorial design. Participants were 
intubated patients in the intensive care units of three French university hospitals. The patients enrolled in the study ( n = 515) 
received either active P/T (n = 130), active M/C (n = 130), both active regimens (n = 129), or placebos only (n = 126) for the 
period of intubation and an additional 24 h. The incidence and incidence rates (per 1,000 study days) of MRSA AI were 
assessed. Due to the absence of a statistically significant interaction between the two regimens, analysis was performed at 
the margins by comparing all patient receiving M/C (n = 259) to all patients not receiving M/C (n = 256), and all patients 
receiving P/T (n = 259) to all patients not receiving P/T (n = 256). 
AQ3 
Results 
Incidence [odds ratio (OR) 0.39, 95 % confidence interval (CI) (0.16–0.96), P = 0.04] and incidence rates [incidence rate 
ratio (IRR) 0.41, 95 % CI 0.17–0.97, P = 0.05] of MRSA AI were significantly lower with the use of M/C. We also observed 
an increase in the incidence (OR 2.50, 95 % CI 1.01–6.15, P = 0.05) and the incidence rate (IRR 2.90, 95 % CI 1.20–
8.03, P = 0.03) of MRSA AI with the use of P/T. 
Conclusion 
Among our study cohort of intubated patients, the use of M/C significantly reduced MRSA AI.  
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Part of this work was presented at the 43rd Annual Meeting of the Infectious Diseases Society of America; San Francisco, 
CA; October 6–9, 2005 (Abstract 600). 
 
 
Introduction 
Methicillin-resistant Staphylococcus aureus (MRSA) is considered to be the most prevalent nosocomial bacterium exhibiting 
multidrug-resistance [1]. MRSA accounted for 8.5 % of the pathogens responsible for healthcare-associated infections 
reported to the National Healthcare Safety Network during the period 2009–2010 [2]. In two studies, the routine screening of 
patients in intensive care units (ICUs) of large university hospitals revealed that 5–15 % of the patients had MRSA at 
admission [3] and up to 10 % had acquired MRSA during their stay in the ICU [4]. More recent estimates of MRSA 
incidence rates have varied from 2 to 14 per 1,000 patient-days, depending on whether infection or colonization is 
considered [5–7]. MRSA colonization increases considerably the risk of subsequent MRSA infection [8, 9]. The strategies to 
control MRSA infections in the ICU remain a controversial issue. Eradication of MRSA carriage with the use of nasal 
mupirocin and/or chlorhexidine body wash has been proposed and is widely recommended in some European countries. The 
mupirocin/chlorhexidine (M/C) regimen has been reported to reduce subsequent S. aureus infections in methicillin-
susceptible S. aureus (MSSA) carriers [10], but a similar effect in MRSA carriers is uncertain. Recently, universal 
decolonization, but not MRSA carrier decolonization, has been shown to reduce the rate of MRSA clinical isolates [6]. 
Selective digestive decontamination (SDD), which primarily uses topical antibiotics (polymyxin and tobramycin), with or 
without systemic antibiotics, has been widely employed to prevent acquired infections (AI) in intubated patients in the ICU. 
SDD has been shown to reduce respiratory tract infections [11] and to improve survival [12, 13]. In a multicenter, placebo-
controlled, randomized, double-blind study performed according to a 2 × 2 factorial design, we have shown that a double 
decontamination regimen using SDD plus a nasal mupirocin and chlorhexidine body wash substantially reduced all -cause 
ICU-AI in intubated patients, whereas each regimen administered alone was ineffective [14]. The objective of the present 
study was to examine whether the M/C regimen would be effective in preventing MRSA AI in intubated patients. For that 
purpose, we performed a post hoc analysis of the entire study population.  
AQ4 
 
Patients and methods 
 
Study design 
The study was conducted at three multidisciplinary medical ICUs at three university -affiliated hospitals in France from April 
1996 to June 1999. The protocol was approved by the regional committee on human investigation and has been reported 
elsewhere [14]. Patients aged >18 years who were intubated for <48 h and likely to require intubation and mechanical 
ventilation for >48 h were eligible for entry. Written consent had to be obtained from either the patient or their next of kin. 
The main exclusion criteria were a high probability of death, brain death, palliative treatments, neutropenia, ongoing trial,  or 
prior decontamination therapy. Of the 4,444 patients who were recruited during the study period, 3,089 did not meet 
inclusion criteria (mostly due to lack of intubation or expected intubation for <2  days) and 655 had one or more defined 
exclusion criterion, leaving 516 eligible patients who were randomized among whom 515 were ul timately analyzed. 
 
Decontamination regimens 
The polymyxin/tobramycin regimen (P/T) did not use systemic antibiotics for the purpose of decontamination. Briefly, a 
solution containing polymyxin E (15 mg/ml) and tobramycin (10 mg/ml) or a gelatin solution (placebo) was administered to 
the nostrils (1 ml × 2), the oropharynx (3 ml), and the stomach (5 ml) every 6 h. The second regimen (M/C) was a nasal 
mupirocin 2 % ointment (Bactroban®; GlaxoSmithKline, Marly-le-Roi, France) and chlorhexidine 4 % soap (Hibiscrub®; 
Astra-Zeneca, Rueil-Malmaison, France) or petroleum jelly (placebo) and a non-antiseptic liquid soap mixed with the 
appropriate concentration of dye (cochineal red) and perfume (herbacol) to mimic the appearance of Hibiscrub ® (placebo). 
Nurses’ aids washed each patient’s body twice daily with 15  ml of soap, followed by rinsing. Three times daily for 5 days, 
approximately 100 mg of nasal ointment was placed in both anterior nares. Following the initial course, additional 5 -day 
courses of nasal ointment (up to two) were given to patients whose nasal swabs were positive for  S. aureus (MSSA or 
MRSA) at follow-up. A nurse was independently in charge of the distribution of the nasal ointment treatment since the 
results of the colonization samples were not revealed to the clinicians during the study. Due to the 2 × 2 factorial design of 
the study, the 515 analyzed patients were allocated to one of the four following treatments: active P/T + placebo for M/C 
(P/T + 0, n = 130), placebo for P/T + active M/C (0 + M/C, n = 130), both active treatments (P/T + M/C, n = 129), or 
placebos only (0 + 0, n = 126) (Table 1). Active treatments or placebos were given during the intubation period plus an 
additional 24 h. 
Table 1 
Baseline characteristics and primary diagnosis in the 515 study patients 
Baseline characteristics 
Treatmentsa 
Pvalue 
P/T + M/C 
(n = 129) 
P/T + 0 
(n = 130) 
0 + M/C 
(n = 130) 
0 + 0 
(n = 126) 
Center, no. of patients (%)         >0.99 
 Brest 23 (18) 24 (19) 24 (18) 20 (16)   
 Rennes 70 (54) 72 (55) 70 (54) 72 (57)   
 Tours 36 (28) 34 (26) 36 (28) 34 (27)   
Age, years (range)a"b" , instead of "a" 68 (21–87) 70 (20–90) 65 (21–86) 67 (19–84) 0.9 
Sex (male/female), no. of 
patients 81/48 85/45 86/44 82/44 0.95 
Origin, no. of patients (%)         0.41 
 Home/emergency 
department 63 (49) 56 (43) 67 (52) 54 (43)   
 Hospital ward 66 (51) 74 (57) 63 (48) 72 (57)   
 Prior length of stay in 
hospital, days (range) 3 (1–68) 4 (1–78) 4 (1–101) 3 (1–71) 0.81 
McCabe score, no. of 
patients (%)         0.24 
 Nonfatal 61 (47) 52 (40) 59 (45) 56 (44)   
 Ultimately fatal 64 (50) 67 (52) 67 (52) 59 (47)   
 Rapidly fatal 4 (3) 11 (8) 4 (3) 11 (9)   
Underlying diseases, no. of 
patients (%)           
 Respiratory (chronic) 44 (34) 41 (32) 44 (34) 38 (30) 0.80 
 Congestive heart failure 33 (26) 36 (28) 34 (26) 27 (21) 0.69 
 Diabetes 14 (11) 18 (14) 21 (16) 17 (13) 0.67 
 Neurology 12 (9) 14 (11) 20 (15) 16 (13) 0.47 
 Liver disease 17 (13) 10 (8) 12 (9) 11 (9) 0.47 
 Cancer 12 (9) 15 (12) 14 (11) 15 (12) 0.91 
Glasgow Coma Score 
(range)b 14 (3–15) 15 (3–15) 15 (3–15) 15 (3–15) 0.58 
Simplified Acute Physiology 
Score II (range)a 44 (15–81) 46 (14–83) 45 (6–80) 46 (18–76) 0.55 
Infection at inclusion, no. of 
patients (%)           
  Community-acquired 48 (37) 55 (42) 48 (37) 45 (36) 0.71 
  Nosocomial, before ICU 
admission 20 (16) 21 (16) 21 (16) 30 (24) 0.26 
  ICU-acquired, before 
inclusion 7 (5) 4 (3) 10 (8) 13 (10) 0.11 
  Antimicrobials within 
3 days of inclusion; no. of 91 (71) 87 (67) 96 (74) 89 (71) 0.68 
patients (%) 
Primary diagnosis, no. of 
patients (%)         0.88 
 Respiratory 45 (35) 48 (37) 46 (35) 43 (34)   
 Neurologic 30 (23) 21 (16) 25 (19) 26 (21)   
 Infection 12 (9) 16 (12) 16 (12) 20 (16)   
 Septic shock 7 (5) 7 (5) 10 (8) 4 (3)   
 Cardiovascular 11 (9) 13 (10) 8 (6) 6 (5)   
 Trauma/surgery 13 (10) 12 (9) 11 (8) 10 (8)   
 Other 11 (9) 13 (10) 14 (11) 17 (13)   
Two-way nonparametric analysis of variance and the Wilcoxon rank-sum test were used for 
continuous variables; the chi-square test or the Fisher’s exact test were used for categorical 
variables 
P/T, Polymyxin/tobramycin regimen, M/C, mupirocin/chlorhexidine regimen, 0, placebo, ICU 
intensive care unit 
aP/T + M/C both active treatment regimens, PT + 0 active P/T treatment + placebo for M/C, 0 + 
MC placebo for P/T + active M/C treatment, 0 + 0 placebos only 
bContinuous variables were medians and range 
 
Report of S. aureus infection and colonization 
All types of infections that were acquired between the randomization and the termination da te of study treatments plus an 
additional 48 h, as defined by the Centers for Disease Control and Prevention [15], were recorded. Infections were 
characterized by site and a maximum of three microorganisms were identified. Only those infections involving  S. 
aureus were considered for the purpose of the present study. S. aureus screening for colonization was performed by 
separately swabbing both nares and the groin area on admission into the ICU every week, then every 2  weeks from day 28 
onwards, and then at the end of study or upon discharge from the ICU. Acquired MRSA or MSSA colonization was defined 
at the time of the first colonization sample (nose, groin) which was found positive for MRSA or MSSA among patients who 
were non-carriers at admission. Staphylococci were identified using standard methods (i.e., catalase, coagulase, and latex 
agglutination; Pastorex; Bio-Rad Laboratories, Marnes-la-Coquettte, France). The antibiotic susceptibility of S. 
aureus isolates was determined using the diffusion method only, with disks containing antibiotics (Bio-Rad) on Mueller–
Hinton agar (Oxoid, Thermo Fisher Scientific, Waltham, MA). Susceptibility or resistance to methicillin was determined 
according to the recommendations of the French Society of Microbiology [16]. 
S. aureus colonization strains were tested for mupirocin resistance using 5-μg disks (Sanofi Diagnostics Pasteur, Marnes-La-
Coquette, France) and E test assays (AB Nordisk, Solna, Sweden) [17]. Strains showing a zone diameter of ≥14 mm around 
5-μg disks were considered to be mupirocin-susceptible, and those presenting diameters of ≤13  mm were considered to be 
mupirocin-resistant (either low-level or high-level resistance). High-level resistance was defined as a minimum inhibitory 
concentration of ≥512 μg/ml (E test). The mupirocin resistance rate was the proportion of all isolates tested that exhibited 
low- or high-level resistance. 
 
Other prevention measures 
Most ICU rooms were single. Standard precautions were applied, in accordance with the French recomme ndations for the 
surveillance and prevention of nosocomial infections (available 
at http://www.sante.gouv.fr/IMG/pdf/100_recommandations.pdf). Care bundles for the maintenance of arterial and central 
venous catheters, peripheral venous catheters, urinary catheters, the prevention of surgical site infection and the management 
of patients under mechanical ventilation were applied according to the institutional guidelines. Chlorhexidine was 
recommended for skin disinfection before the insertion of an intravascular device. Because the results of S. aureusscreening 
were concealed, contact precautions for MRSA were taken based on the results of clinical cultures.  
 
Endpoints 
Rates of MRSA AI were the main endpoint of the present study. We calculated both the incidence (proportion of patients 
who acquired MRSA infection) and the incidence rate of MRSA AI expressed per 1,000 study days. As secondary endpoints, 
we examined MSSA and overall S. aureus AI and acquired colonization for MRSA and MSSA. The decolonization rate was 
calculated as the proportion of MRSA or MSSA carriers (either at admission to the ICU or during hospitalization in the ICU) 
in whom all subsequent screening tests (both nares and groin) were negative. This represents the analysis of data which had 
been collected prospectively at the time of the trial but not analyzed in the initial report [14]. 
 
Statistical analysis 
Statistical analysis was performed using SAS statistical software ver. 9.3 (SAS Institute, Cary, NC). Differences in incidenc e 
were assessed using a logistic regression model and expressed with an odds ratio (OR) and 95  % confidence interval (CI). 
Incidence rates were tested using a Poisson regression model or a zero-inflated Poisson model, as appropriate, and expressed 
as an incidence rate ratio (IRR). A zero-inflated Poisson regression model was used when the data showed a higher incidence 
of zero counts than would be expected if the data were Poisson distributed [18]. We first used a complete regression model, 
which simultaneously tested the effect of each active regimen and their interaction. Because the interaction was not 
statistically significant (P value ≥0.30 for all comparisons), we finally performed analysis “at the margins”, rather than 
“inside the table”. The former analysis is appropriate to factorial trials when the two treatments are considered to act 
independently [19]. Based on a prior surveillance period, the sample size (125 patients per group) had been initially powered 
to detect a 50 % reduction of the number of AI per patient (α = 5 %; β = 10 %) under the assumption of no statistically 
significant interaction. In the final model, we compared the 259 patients who received active M/C treatment (all M/C) to the 
256 patients who received the corresponding placebo (all no M/C). Comparisons between the patients who received active 
P/T treatment (all P/T, n = 259) and those who did not (all no P/T, n = 256) were also conducted, but these results did not 
represent the main objective of the study. A P value of ≤0.05 was considered to be statistically significant.  
 
 
Results 
 
Study patients 
Among the 4,444 patients recruited during the study, 2,736 (61.6 %) were not included because they had an expected 
duration of intubation of <48 h and  1,192  were not included due to the following reasons: age <18 years(1.0 %), intubation 
>48 h before admission (5.5 %), absence of consent or refusal (7.5 %), presence of one or more exclusion criteria (8.6 %), 
and/or clinical considerations or logistic problems (4.1 %). Baseline characteristics and primary diagnosis of the 515 
analyzed patients were similar in the four groups (Table 1). 
 
Effect of M/T treatment on MRSA-acquired infections 
Compared to the corresponding placebo, the use of the M/C treatment regimen resulted in a statistically significant reduction 
in the incidence of MRSA infection [6.6 vs. 2.7 %, respectively; OR 0.39, 95 % CI 0.16–0.96, P = 0.04] (Table 2). The 
reduction was similar in the patients who received the P/T treatment regimen (comparison of P/T  + M/C to P/T + 0: 
OR 0.40) and in those who did not receive P/T treatment (comparison of 0  + M/C to 0 + 0: OR 0.38). The incidence rates of 
MRSA AI were also reduced as well [2.0 ‰ vs. to 4.9 ‰; IRR 0.41, 95 % CI 0.17–0.97, P = 0.05]. The IRRs were also 
similar when P/T + M/C was compared to P/T + 0 (IRR 0.44) and when 0 + M/C was compared to 0 + 0 (IRR 0.39). 
Table 2 
Incidence and incidence rates of methicillin-resistant Staphylococcus aureus, methicillin-
sensitive S. aureus, and overall S. aureus infections 
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Treatment 
regimens/infection 
type 
M/C treatment 
regimen 
Interaction Pvalue 
Estimate 
of the 
risk (95 
% CI) 
Pvalue Margin 
Yes No 
Polymyxin/tobramycin 
(P/T):  Yes P/T + M/C P/T + 0       All P/T 
 MRSA-acquired infection 
   Incidence (%) 5/129 (3.9) 
12/130 
(9.2)   
0.40 
(0.11–
1.26) 
0.13 17/259 (6.6) 
   Incidence ratea (‰) 6/1,972 (3.0) 
16/2,315 
(6.9)   
0.44 
(0.14–
1.18) 
0.11 22/4,287 (5.1) 
 MSSA-acquired infection 
   Incidence (%) 2/129 (1.6) 
2/130 
(1.5)   
1.01 
(0.07–
14.10) 
1.00 4/259 (1.5) 
   Incidence ratea (‰) 2/1,972 (1.0) 
2/2,315 
(0.9)   
1.17 
(0.09–
16.20) 
0.87 4/4,287 (0.9) 
 S. aureus-acquired infection 
   Incidence (%) 7/129 14/130   
0.48 
(0.16–
1.32) 
0.18 21/259 (8.1) 
   Incidence ratea (‰) 8/1,972 18/2,315   
0.52 
(0.20–
1.26) 
0.11 26/4,287 (6.1) 
Polymyxin/tobramycin 
(P/T): No 0 + M/C 0 + 0       
All no 
P/T 
 MRSA-acquired infection 
   Incidence (%) 2/130 (1.5) 
5/126 
(4.0)   
0.38 
(0.04–
2.37) 
0.42 7/256 (2.7) 
   Incidence ratea (‰) 2/1,991 (1.0) 
5/1,961 
(2.5)   
0.39 
(0.04–
2.41) 
0.24 7/3,952 (1.8) 
 MSSA-acquired infection 
   Incidence (%) 2/130 (1.5) 
7/126 
(2.6)   
0.27 
(0.03–
1.44) 
0.16 9/256 (3.5) 
   Incidence ratea (‰) 4/1,991 (2.0) 
8/1,961 
(4.1)   
0.49 
(0.11–
1.84) 
0.68 12/3,952 (3.0) 
 S. aureus-acquired infection 
   Incidence (%) 4/130 (3.1) 
11/126 
(8.7)   
0.33 
(0.08–
1.16) 
0.09 15/256 (5.9) 
   Incidence ratea (‰) 6/1,991 13/1,961   0.45 0.23 19/3,952 
(3.0) (6.6) (0.14–
1.28) 
(4.8) 
Margin All M/C All no M/C Interaction Pvalue       
 MRSA-acquired infection 
   Incidence (%) 7/259 (2.7) 
17/256 
(6.6) 0.96 
0.39 
(0.16–
0.96) 
0.04   
   Incidence ratea (‰) 8/3,963 (2.0) 
21/4,276 
(4.9) 0.87 
0.41 
(0.17–
0.97) 
0.05   
 MSSA-acquired infection 
   Incidence (%) 4/259 (1.5) 
9/256 
(3.5) 0.30 
0.43 
(0.13–
1.40) 
0.16   
   Incidence ratea (‰) 6/3,963 (1.5) 
10/4,276 
(2.3) 0.68 
0.65 
(0.21–
1.93) 
0.76   
 S. aureus-acquired infection 
   Incidence (%) 11/259 (4.2) 
25/256 
(9.8) 0.64 
0.41 
(0.20–
0.85) 
0.02   
   Incidence ratea (‰) 14/3,963 (3.5) 
31/4,276 
(7.2) 0.89 
0.49 
(0.25–
0.95) 
0.05   
MRSA, Methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus; CI 
confidence interval 
aIncidence rates are expressed per 1,000 study days. The number of study days in the 
randomization groups was 1,972 (P/T + M/C), 2,315 (P/T + 0), 1,991 (0 + M/C), and 1,961 (0 + 0) 
 
Effect of M/C treatment regimen on MSSA and overall S. aureus infections 
With respect to MSSA AI, treatment with M/C alone did not result  in a statistically significant reduction in the incidence 
(1.5 and 3.5 %; OR 0.43, 95 % CI 0.13–1.40; P = 0.16) or in the incidence rates (1.5 and 2.3 ‰; OR 0.65, 95 % CI 0.21–
1.93, P = 0.76). With respect to overall S. aureus AI, treatment with M/C significantly reduced the incidence (all M/C vs. all 
no M/C: OR 0.41, 95 % CI 0.20–0.85, P = 0.02; P/T + M/C vs. P/T + 0: OR 0.48; 0 + M/C vs. 0 + 0: OR 0.33) and incidence 
rates [all M/C vs. all no M/C: IRR 0.49, 95 % CI 0.25–0.95, P = 0.05; P/T + M/C vs. P/T + 0: IRR 0.52; 0 + M/C vs. 0 + 0: 
OR 0.45] (Table 2). 
 
Site of S. aureus-acquired infections 
The sites of origin of the 45 S aureus AI are shown in Table 3. Twenty-nine AI were due to MRSA and 16 to MSSA. The 
most frequent site was pneumonia, which was ventilator-associated in all cases (MRSA n = 9; MSSA n = 9). There was a 
nonsignificant trend for a reduction in MRSA AI at any site with the use of M/C, except for catheter -related urinary tract 
infection. Due to the small number of infections, the decline in the rates of MSSA pneumonia with the use of M/C as 
compared to the corresponding placebos was not tested. 
Table 3 
Sites of S. aureus-acquired infections 
Variables All groups P/T + M/C P/T + 0 0 + M/C 0 + 0 
M/C P/T 
Yes No Yes No 
MRSA-acquired infection (n) 
 Pneumonia 9 1 5 1 2 2 7 6 3 
 Urinary tract infection 6 2 3 1 0 3 3 5 1 
 Bloodstream 5 1 3 0 1 1 4 4 1 
 Other 9 2 5 0 2 2 7 7 2 
  Catheter site 3 1 1 0 1 1 2 2 1 
  Ear/nose/throat 3 0 3 0 0 0 3 3 0 
  Hepatodigestive 2 1 1 0 0 1 1 2 0 
  Skin 1 0 0 0 1 0 1 0 1 
 Total 29 6 16 2 5 8 21 22 7 
  Infection with 
colonization 18 3 12 1 2 4 14 15 3 
  Infection without 
colonization 11 3 4 1 3 4 7 7 4 
MSSA-acquired infection (n)  
 Pneumonia 9 0 1 2 6 2 7 1 8 
 Bloodstream 2 1 0 1 0 1 1 0 2 
 Other 5 1 1 1 2 2 3 2 3 
  Catheter site 3 1 0 1 1 2 1 1 2 
  Ear/nose/throat 2 0 1 0 1 0 2 1 1 
 Total 16 2 2 4 8 6 10 4 12 
  Infection with 
colonization 11 1 1 4 5 5 6 2 9 
  Infection without 
colonization 5 1 1 0 3 1 4 2 3 
 
 
S. aureus colonization and impact of M/C regimen 
Samples for colonization were not obtained for six of the 515 study patients. At the time of randomization, 121 patients 
(22.8 %) were found to be colonized with MSSA (nose n = 72; groin n = 22; nose and groin n = 27) and 54 (10.6 %) with 
MRSA (nose n = 20; groinn = 34; nose and groin n = 10). With the use of M/C, MRSA acquisition was nonsignificantly 
lower than the corresponding placebo (incidence: 7.9 vs. 12.9 %, respectively, P = 0.15; incidence rate: 5.8 vs. 9.0 ‰, 
respectively, P = 0.09) (Table 4). S. aureuscolonization was not present prior to or at the time of diagnosis in 16 of the 45  S. 
aureus AIs (35.6 %; 5/16 MSSA AI; 11/29 MRSA AI). The decolonization rate for MRSA was significantly higher with the 
use of M/C (69.2 %) than without M/C (41.9 %; P = 0.04), but not with the use of P/T (60.0 %) versus no P/T 
(48.1 %; P = 0.36; P value for the interaction 0.89). The decolonization rate for MSSA was higher in the M/C 
(87 %, P = 0.004) and P/T + M/C (93.3 %, P = 0.003) groups than in the groups not receiving either treatment regimen 
(48.1 %). 
Table 4 
Acquisition of S. aureus colonization in the intensive care unit 
Variables P/T + M/C (n = 129) 
P/T + 0 
(n = 130) 
0 + M/C 
(n= 130) 
0 + 0 
(n = 126) InteractionP value 
M/C P/T 
Yes 
(n = 259) 
No 
(n = 256) Pvalue 
Yes 
(n = 259) 
No 
(n = 256) Pvalue 
MRSA-acquired colonization 
 No. of patients/no. 
not colonized at 
admission (%) 
10/113 
(8.8) 
17/116 
(14.7) 
8/115 
(6.9) 
12/111 
(10.8) 0.89 
18/228 
(7.9) 
29/227 
(12.8) 0.15 
27/229 
(11.8) 
20/226 
(8.8) 0.32 
 Incidence rate (‰)a 10/1,545 (6.5) 
17/1,680 
(10.1) 
8/1,546 
(5.2) 
12/1,539 
(7.8) 0.95 
18/3,091 
(5.8) 
29/3,219 
(9.0) 0.09 
27/3,225 
(8.4) 
20/3,085 
(6.5) 0.40 
MSSA-acquired colonization 
 No. of patients/no. 
not colonized at 
admission(%)a 
2/99 (2.0) 5/104 (4.8) 
2/94 
(2.1) 
4/91 
(4.4) 0.90 
4/193 
(2.1) 
9/195 
(5.1) 0.18 
7/203 
(3.4) 
6/185 
(3.2) 0.93 
 Incidence rate (‰) a 2/1,342 (1.5) 
5/1,648 
(3.0) 
2/1,395 
(1.4) 
4/1,230 
(3.3) 0.93 
4/2,737 
(1.5) 
9/2,878 
(3.1) 0.19 
7/2,990 
(2.3) 
6/2,625 
(2.3) 0.95 
 Rate of MRSA 
decolonization,n (%) 
10/14 
(71.4) 
8/16 
(50.0) 
8/12 
(66.7) 
5/15 
(33.3) 0.89 
18/26 
(69.2) 
13/31 
(41.9) 0.04 
18/30 
(60.0) 
13/27 
(48.1) 0.38 
 Rate of MSSA 
decolonization,n (%) 
14/15 
(93.3) 
16/20 
(80.0) 
20/23 
(87.0) 
13/27 
(48.1) 0.04             
aIncidence rates in each group are expressed per 1,000 patient-days at risk. They are calculated as the numbers of patients who acquired colonization 
divided by the total number of patient-days at risk in each group 
 
Impact of P/T treatment on S. aureus infection and colonization 
Treatment with P/T compared with the placebo was associated with an increase in the incidence (6.6 vs. 2.7  %, respectively, 
OR 2.50, 95 % CI 1.01–6.15, P = 0.05) and the incidence rate [5.1 vs. 1.8 ‰, respectively, IRR 2.90, 95 % CI 1.20–
8.03, P = 0.03) of MRSA AI. The reduction in MSSA AI was not statistically significant (incidence: OR 0.43, 95 % CI 0.13–
1.40; incidence rate: IRR 0.31, 95 % CI 0.07–1.02). Overall, S. aureus AI incidence (8.1 vs. 5.9 %, P = 0.33) and incidence 
rate (6.1 vs. 4.8 ‰,P = 0.61), MRSA- and MSSA-acquired colonization, and the MRSA decolonization rate (Table 4) were 
not significantly changed with the P/T treatment. 
 
Mupirocin resistance 
High-level mupirocin resistance was not detected. At randomization, 14 of the  509 screened patients (2.8 %) were colonized 
with low-level mupirocin-resistant S. aureus (P/T + M/C: 4/129; P/T + 0: 2/128; 0 + M/C: 4/129; 0 + 0: 4/123; P = 0.83). 
Following week 1, 15 of the 495 patients (3 %) who were initially non-carriers were diagnosed with low-level mupirocin-
resistant S. aureus colonization (P/T + M/C: 1/125; P/T + 0: 2/126; 0 + M/C: 8/125; 0 + 0: 4/119; P = 0.06). Of a total of 
2,230 screening samples that were collected at both sites on admission and during follow-up, 203 and 218 tested culture 
positive for MRSA and MSSA, respectively. The mupirocin resistance rate was 20.2  % for MRSA and 1.8 % for MSSA 
colonization isolates (P < 0.001), and there were 0/18 MRSA clinical isolates. Among the 29 patients colonized with 
mupirocin-resistant S. aureus, 27 did not acquire a S. aureus infection. Two patients colonized with mupirocin-resistant 
MSSA had MSSA AI (mupirocin sensitivity not tested on clinical isolates).  
 
Adverse events 
Treatment with the nasal ointment was discontinued due to discomfort in three patients who received the active mupirocin 
and in five who received the placebo. Skin allergy was reported in six patients receiving M/C and in six patients receiving 
the corresponding placebos. Body washing was discontinued due to allergy in five patients who received the active 
chlorhexidine, in three who received the liquid soap, and for other reasons in eight patients (P/T  + M/C: 1; P/T + 0: 2; 
0 + M/C: 3; 0 + 0: 3). 
 
 
Discussion 
The main result of this study was that the use of nasal mupirocin combined with chlorhexidine body wash in patients 
requiring intubation for >48 h was able to reduce MRSA ICU-acquired infections. Because this is a post hoc analysis of a 
previously published trial, the sample size was not calculated to specif ically assess MRSA AI. This represents a limitation of 
the study which could result in inadequate power to detect a statistically significant interaction and thereby reduce the sco pe 
of the comparisons. Because the estimates of the risk for MRSA AI with the use of M/C were very similar in the “at the 
margins” analysis and in the two pairwise comparisons between groups, interaction was unlikely. This strengthens our 
conclusion on the reduction of MRSA AI with the use of M/C. 
Although a decline in MRSA incidence rates [20] and in MRSA acquisition [21] has been reported in some European 
countries, great variations persist between countries and between types of hospital care, and MRSA is still considered a 
public health priority [22]. The methicillin resistance rate (proportion of MRSA among all S. aureus isolates) is >25 % in 
more than one-fourth of countries (available athttp://www.ecdc.europa.eu/en/eaad/documents/eaad-2011-summary-
antimicrobial-resistance-data.pdf) in the EU. This indicator is commonly used for the surveillance of MRSA because it 
correlates with MRSA incidence rates [23]. In France in 2010, the MRSA incidence rate in the ICU was approximately 
threefold higher (1.14 per 1,000 patient-days) than the overall incidence rate (0.40) [24].S. aureus was involved in 12.2 % of 
AI (total AI incidence 13.2 %) and the methicillin resistance rate was 35.0 % (vs 48.7 % in 2004) (available 
at http://www.cclinparisnord.org/REACAT/REA2010/Rapport_REA2010.pdf). In the STAR*ICU trial, 6.2–24.3 % of 
patients, depending on centers, had surveillance cultures positive for MRSA within 2 days of ICU admission, On average, 
the incidence of MRSA colonization/infection was 13.9 per 1,000 patient-days at risk (range 3.8–49.0), highlighting a high 
variability between periods and ICUs in the USA (Supplementary Appendix [7]). Moreover, intubated patients have an 
approximately eightfold higher risk for MRSA acquisition [25] or infection [26] than those who are not intubated in the ICU. 
In our study, there were high rates of MRSA colonization at admission and during the ICU stay as opposed to relatively low 
infection rates. Because the majority of S. aureus infections were associated with colonization, effective decolonization of 
MRSA-colonized patients was a likely explanation to the reduction in MRSA AI. The absence of molecular typing of MRSA 
isolates is a limitation of the study, and we could not be sure that colonization and clinical isolates were identical in all  cases 
of infection. We previously reported that the clonal nature of epidemic MRSA stains recovered during a 9-year period at our 
institution could not be easily distinguished by pulsed-field gel electrophoresis [27, 28]. 
Decontamination with various topical agents has been attempted to prevent MRSA AI. The aim is to re duce both cross-
transmission and the risk of subsequent infection among MRSA carriers. Nasal mupirocin decontamination alone may not be 
effective because of the persistence of MRSA carriage at other anatomic sites [29]. Skin decontamination with chlorhexidine 
body washing has been reported to significantly reduce MRSA acquisition, but not infection, in ICUs [ 30]. Ridenour et al. 
[31] reported a reduction in the incidence of acquired MRSA colonization and infection with the combined use of intranasal 
mupirocin with chlorhexidine body wash. Unlike the typical MRSA decolonization strategies targeting only MRSA carriers, 
in our study all patients immediately received nasal ointment (active mupirocin or placebo), and the results of  S. 
aureus colonization samples were concealed to the clinicians. The absence of delay for decolonization of MRSA carriers 
could reduce the risk of cross-transmission. Moreover, whole-body washing with chlorhexidine may also notably reduce 
MRSA loads at extra-nasal sites, especially at the groin area [32]. Furthermore, we washed our intubated patients twice 
daily, which was twice more frequent than that usually reported for decolonization [5, 6]. Taken altogether, these factors 
could explain the level of prophylaxis achieved. 
Although the study was performed more than one decade ago, due to the double-blind, placebo-controlled design, we believe 
the conclusion is still relevant to current practice in ICUs where MRSA prevalence rate remains substantial. The 
administration of M/C to patients intubated for an expected duration of >48 h targeted the patients at highest risk for MRSA 
AI. These patients represented 38 % of the 4,444 patients admitted to the three ICUs during the study period. This protocol 
could be more selective than universal decolonization applied to all ICU patients, which has been shown to significantly 
reduce the rates of MRSA clinical isolates, as well as reduce MRSA bloodstream infections, but not significantly [ 6]. 
Moreover, the combination of M/C with the P/T regimen achieved a substantial reduction in all-cause infections [14]. 
Our study also showed that the use of P/T was associated with a statistically significant increase in MRSA infection rates. 
Earlier studies reported an increase in MRSA isolates with the use of SDD [33–35], although the exact rates of MRSA AI 
were not calculated, and statistical significance not assessed. Due to the introduction of community -acquired MRSA (mostly 
susceptible to tobramycin) in the hospital setting and changing epidemiology in hospit al-acquired MRSA, the impact of P/T 
on MRSA infection rates deserves re-assessment. MRSA-acquired colonization remained essentially unchanged with the use 
of P/T. 
The M/C regimen was effective in decolonizing MSSA. No definite conclusion on MSSA AI could b e drawn due to 
insufficient number of infections. 
The mupirocin-resistant S. aureus prevalence rate on admission was considered to be moderate, similar to the acquisition 
rate in ICU. With the routine or widespread use of nasal mupirocin to control endemic  S. aureus infection and transmission 
rates among general inpatient populations, the emergence of mupirocin resistance has been commonly observed, [ 36, 37], 
although it is not a universal trend [38, 39]. Resistance rates have varied from 7 to 65 % [40, 41]. The clinical significance of 
low-level resistance remains unclear, and the combined use of chlorhexidine with mupirocin might have limited the 
emergence of mupirocin resistance in our study. Genotypic chlorhexidine resistance, which may explain the failu re of 
decolonization with M/C treatment in low-level mupirocin-resistant MRSA strains [42] was not tested. 
In conclusion, the combined use of nasal mupirocin and chlorhexidine body wash significantly reduced the rates of MRSA 
AI in intubated patients. Surveillance of mupirocin resistance is mandatory with the use of mupirocin.  
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